AKBA
Price:
$1.88
Market Cap:
$410.18M
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Otsu...[Read more]
Industry
Biotechnology
IPO Date
2014-03-20
Stock Exchange
NASDAQ
Ticker
AKBA
According to Akebia Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is 129.56%. This represents a change of 301.24% compared to the average of 32.29% of the last 4 quarters.
The mean historical ROE of Akebia Therapeutics, Inc. over the last ten years is -187.01%. The current 129.56% ROE has changed -169.28% with respect to the historical average. Over the past ten years (40 quarters), AKBA's ROE was at its highest in in the March 2023 quarter at 116.62%. The ROE was at its lowest in in the September 2022 quarter at -402.34%.
Average
-187.01%
Median
-67.65%
Minimum
-1134.76%
Maximum
169.78%
Discovering the peaks and valleys of Akebia Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 329.95%
Maximum Annual ROE = 169.78%
Minimum Annual Increase = -114.96%
Minimum Annual ROE = -1134.76%
Year | ROE | Change |
---|---|---|
2023 | 169.78% | -114.96% |
2022 | -1134.76% | 254.31% |
2021 | -320.28% | 126.67% |
2020 | -141.29% | 99.44% |
2019 | -70.84% | 162.07% |
2018 | -27.03% | -58.06% |
2017 | -64.45% | -67.66% |
2016 | -199.28% | 329.95% |
2015 | -46.35% | 30.26% |
2014 | -35.58% | -16.89% |
The current ROE of Akebia Therapeutics, Inc. (AKBA) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-428.42%
5-year avg
-299.48%
10-year avg
-187.01%
Akebia Therapeutics, Inc.’s ROE is greater than Protalix BioTherapeutics, Inc. (-30.89%), greater than Cidara Therapeutics, Inc. (-219.21%), greater than X4 Pharmaceuticals, Inc. (-32.51%), less than Seres Therapeutics, Inc. (60.75%), less than AVROBIO, Inc. (29.68%), greater than CohBar, Inc. (-58.44%), less than Ocean Biomedical, Inc. (64.85%), greater than Enveric Biosciences, Inc. (-201.01%), greater than Elevation Oncology, Inc. (-59.73%), greater than Hepion Pharmaceuticals, Inc. (-505.74%),
Company | ROE | Market cap |
---|---|---|
-30.89% | $124.44M | |
-219.21% | $143.75M | |
-32.51% | $57.64M | |
60.75% | $131.23M | |
29.68% | $5.24M | |
-58.44% | $1.45M | |
64.85% | $24.95M | |
-201.01% | $3.31M | |
-59.73% | $35.67M | |
-505.74% | $4.62M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Akebia Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Akebia Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the ROE?
How can you use the ROE?
What is Akebia Therapeutics, Inc.'s ROE?
How is the ROE calculated for Akebia Therapeutics, Inc. (AKBA)?
What is the highest ROE for Akebia Therapeutics, Inc. (AKBA)?
What is the 3-year average ROE for Akebia Therapeutics, Inc. (AKBA)?
What is the 5-year average ROE for Akebia Therapeutics, Inc. (AKBA)?
How does the current ROE for Akebia Therapeutics, Inc. (AKBA) compare to its historical average?